Testing effectiveness (Phase 2)Study completedNCT01613118
What this trial is testing
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Who this might be right for
Focal Segmental Glomerulosclerosis
Travere Therapeutics, Inc. 109